Harrow, Inc. announced a multi-year exclusive partnership with Asembia, a provider of specialty pharmacy and patient support hub services, to launch a new nationwide digital patient access solution. This collaboration aims to expand access to Harrow's ophthalmic branded products by simplifying the prescribing process for eyecare professionals.
The partnership will leverage ASPN Pharmacies, Asembia's non-dispensing pharmacy, to streamline the prescription journey from intake and benefits verification to prior authorization and co-pay support. This is expected to improve both accessibility and affordability for patients, ensuring faster access to critical eyecare medications.
The program covers a wide range of Harrow's branded products, including FLAREX, ILEVRO, MAXIDEX, MAXITROL, NATACYN, NEVANAC, TOBRADEX ST, VERKAZIA, VEVYE, VIGAMOX, and ZERVIATE. By automating the refill process and providing complete transparency, the initiative is designed to drive greater patient compliance and better health outcomes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.